1. Home
  2. HUBS vs CORT Comparison

HUBS vs CORT Comparison

Compare HUBS & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo HubSpot Inc.

HUBS

HubSpot Inc.

HOLD

Current Price

$191.71

Market Cap

9.5B

Sector

Technology

ML Signal

HOLD

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

HOLD

Current Price

$89.23

Market Cap

9.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HUBS
CORT
Founded
2005
1998
Country
United States
United States
Employees
N/A
730
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.5B
9.7B
IPO Year
2014
2001

Fundamental Metrics

Financial Performance
Metric
HUBS
CORT
Price
$191.71
$89.23
Analyst Decision
Strong Buy
Buy
Analyst Count
32
5
Target Price
$435.19
$96.50
AVG Volume (30 Days)
1.5M
957.9K
Earning Date
05-07-2026
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
855.56
N/A
EPS
0.62
N/A
Revenue
$375,612,000.00
$761,407,000.00
Revenue This Year
$20.46
$26.08
Revenue Next Year
$16.01
$26.98
P/E Ratio
$309.82
N/A
Revenue Growth
N/A
12.79
52 Week Low
$169.63
$28.66
52 Week High
$568.16
$91.00

Technical Indicators

Market Signals
Indicator
HUBS
CORT
Relative Strength Index (RSI) 49.77 80.68
Support Level $187.45 $76.41
Resistance Level $258.01 N/A
Average True Range (ATR) 9.57 3.76
MACD 1.82 -0.09
Stochastic Oscillator 88.34 94.20

Price Performance

Historical Comparison
HUBS
CORT

About HUBS HubSpot Inc.

HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Share on Social Networks: